Related Experiment Video
Updated: Feb 3, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
[Aryl-hydrocarbon receptor as a potential target for anticancer therapy]
J E Vorontsova1, R O Cherezov1, B A Kuzin1
1Koltzov Institute of Developmental Biology of Russian Academy of Sciences, Moscow, Russia.
Abstract:
Aryl-hydrocarbon receptor (Aryl Hydrocarbon Receptor, AHR) is a ligand-dependent transcription factor, whose functions are related to xenobiotic detoxification, response to inflammation, and maintenance of tissue homeostasis. Recent investigations suggest that AHR also plays an important role in the processes of carcinogenesis. Increased expression of AHR is observed in several types of tumors and tumor cell lines. In addition, it turned out that the composition of pharmaceutical drugs used in oncotherapy includes some ligands AHR. These facts allow us to consider an aryl-hydrocarbon receptor as a potential target for anticancer therapy, especially for the treatment of severe cancers whose treatment options are very limited or do not exist at all. In this review the examples of AHR ligands' effect on tumor cell cultures and on model mice lines with AHR-dependent response are discussed.
Insights
The aryl-hydrocarbon receptor (AHR) is involved in cancer development and may be a therapeutic target. AHR ligands show potential in preclinical models for treating difficult cancers.
Area of Science:
- Molecular Biology
- Oncology
- Pharmacology
Background:
- The aryl-hydrocarbon receptor (AHR) is a transcription factor regulating detoxification, inflammation, and tissue homeostasis.
- AHR signaling is increasingly implicated in carcinogenesis, with elevated AHR expression found in various tumors.
- Some anticancer drugs contain AHR ligands, suggesting a role in cancer therapy.
Purpose of the Study:
- To review the role of AHR in cancer.
- To explore AHR as a potential therapeutic target for anticancer therapy, particularly for challenging cancers.
- To discuss the effects of AHR ligands on tumor cell cultures and preclinical cancer models.
Main Methods:
- Literature review of AHR functions in carcinogenesis.
- Analysis of AHR expression in tumor types and cell lines.
- Discussion of preclinical data on AHR ligands in cancer models.
Main Results:
- AHR plays a significant role in cancer development.
- AHR is overexpressed in multiple cancer types.
- AHR ligands demonstrate effects on tumor cells and in animal models.
Conclusions:
- The aryl-hydrocarbon receptor is a promising target for novel anticancer therapies.
- Targeting AHR may offer new treatment strategies for cancers with limited options.
- Further research into AHR ligands is warranted for clinical application in oncology.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Nomenclature of Aryl and Heterocyclic Amines
Internal Receptors
Aromatic Hydrocarbon Anions: Structural Overview
Due to the absence of continuous...
Aromatic Hydrocarbon Cations: Structural Overview
Removing one hydrogen from the intervening CH2 group...
Gene Therapy

